Effects of flecainide on the electrophysiologic properties of isolated canine and rabbit myocardial fibers
- PMID: 3968315
- DOI: 10.1016/s0735-1097(85)80051-6
Effects of flecainide on the electrophysiologic properties of isolated canine and rabbit myocardial fibers
Abstract
The electrophysiologic properties of flecainide, a new potent antiarrhythmic drug, are poorly defined. In this study, they were investigated by standard microelectrode technique in isolated cardiac muscle from rabbit and dog hearts. The concentrations of flecainide used were between 0.1 and 10.0 micrograms/ml. Flecainide produced a concentration-dependent decrease in maximal rate of rise of phase 0 of the action potential (Vmax), action potential amplitude and overshoot potential with an increase in the effective refractory period in ventricular muscle. Vmax was reduced by 52.5% after 1 microgram/ml of flecainide (p less than 0.001) and by 79.8% after 10.0 micrograms/ml (p less than 0.001). The corresponding values for Purkinje fibers were 18.6% (p less than 0.01) and 70.8% (p less than 0.001), respectively, but in these fibers the effective refractory period was shortened at the lower concentration and restored to control value at the higher concentration. The depression of Vmax by flecainide was frequency-dependent. The action potential duration was lengthened by flecainide in ventricular muscle and shortened in Purkinje fibers. At high concentrations (10 micrograms/ml), flecainide depressed slow channel-dependent fibers. Purkinje fiber automaticity induced by isoproterenol was slowed by flecainide. The data indicate that the overall electrophysiologic effects of flecainide in isolated cardiac muscle are complex with a major depressant action on Vmax that may account for its dominant antiarrhythmic effects. It is also possible that the differential effects of the compound on the action potential duration and refractoriness in ventricular muscle and Purkinje fibers contribute to the known arrhythmogenic potential of the drug.
Similar articles
-
Clinical electrophysiologic effects of flecainide acetate.Cardiovasc Drugs Ther. 1988 Mar;1(6):599-603. doi: 10.1007/BF02125745. Cardiovasc Drugs Ther. 1988. PMID: 3155304 Review.
-
Electrophysiologic effects of detajmium on isolated dog cardiac ventricular and Purkinje fibers.J Cardiovasc Pharmacol. 1994 Oct;24(4):559-65. doi: 10.1097/00005344-199410000-00006. J Cardiovasc Pharmacol. 1994. PMID: 7528838
-
Electrophysiologic effects of a new antiarrhythmic agent, recainam, on isolated canine and rabbit myocardial fibers.J Am Coll Cardiol. 1988 Apr;11(4):875-81. doi: 10.1016/0735-1097(88)90225-2. J Am Coll Cardiol. 1988. PMID: 3351157
-
Effects of flecainide on the cellular electrophysiology of neonatal and adult cardiac fibers.Am Heart J. 1987 Jan;113(1):70-6. doi: 10.1016/0002-8703(87)90011-1. Am Heart J. 1987. PMID: 3099562
-
The contribution of cellular electrophysiology in the development of antiarrhythmic agents.Pacing Clin Electrophysiol. 1982 Mar;5(2):238-50. doi: 10.1111/j.1540-8159.1982.tb02220.x. Pacing Clin Electrophysiol. 1982. PMID: 6176964 Review. No abstract available.
Cited by
-
Short-coupled Purkinje ectopy inducible by pharmacological and hyperventilation tests.HeartRhythm Case Rep. 2023 Oct 31;10(1):68-71. doi: 10.1016/j.hrcr.2023.10.025. eCollection 2024 Jan. HeartRhythm Case Rep. 2023. PMID: 38264118 Free PMC article. No abstract available.
-
Flecainide-induced Increase in QRS Duration and Proarrhythmia during Exercise.Clin Drug Investig. 1997 Jun;13(6):326-37. doi: 10.2165/00044011-199713060-00005. Clin Drug Investig. 1997. PMID: 27519494
-
Antiarrhythmic drug classifications. A critical appraisal of their history, present status, and clinical relevance.Drugs. 1991 May;41(5):672-701. doi: 10.2165/00003495-199141050-00002. Drugs. 1991. PMID: 1712704 Review.
-
Adverse effects of class I antiarrhythmic drugs.Drug Saf. 1997 Jul;17(1):8-36. doi: 10.2165/00002018-199717010-00002. Drug Saf. 1997. PMID: 9258628 Review.
-
Clinical electrophysiologic effects of flecainide acetate.Cardiovasc Drugs Ther. 1988 Mar;1(6):599-603. doi: 10.1007/BF02125745. Cardiovasc Drugs Ther. 1988. PMID: 3155304 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources